Biomatter is a Vilnius, Lithuania-based synthetic biology company using generative AI to design proteins and enzymes from scratch. Its Intelligent Architecture platform combines generative models with synthetic biology to create novel enzymes and proteins tailored for therapeutic, industrial, food, and environmental applications, spanning use cases where natural enzymes fall short. By generating sequences beyond the limits of natural evolution, Biomatter targets functions and conditions that conventional protein engineering cannot reach, then validates designs experimentally. The company partners with industrial and life-science organizations to bring AI-designed biocatalysts to market. Biomatter has drawn European venture and strategic backing to scale its generative design platform, positioning itself among Europe's emerging generative-biology players. Its mission is to make protein design programmable and broadly applicable across the bioeconomy.
Biomatter
ActiveGenerative AI for protein and enzyme design across industries
Total raised
$7M
1 round
Stage
Seed
Team
11-50
since 2019
Pricing
Freemium
free plan
Founded
2019
Vilnius
Agent-ready
—
Intelligent Architecture design platform
Generative protein and enzyme design
De novo sequence generation
Therapeutic and industrial enzymes
Synthetic biology validation
Beyond-natural-evolution functions
Biocatalyst engineering
Cross-industry applications
10/100
Early
MCP server
Public API
Webhooks
OAuth 2.0
SDKs
No public agent surfaces detected yet.
— Seed $7M incl. Inventure +3
Capital network
$7M raised ·4 backers·7 network links
- Backers4
- Shared portfoliocompanies these backers also fund
- Extended networkfunds that co-invest alongside them
Isomorphic Labs
Drug Discovery
Terray Therapeutics
Generative AI and ultra-high-throughput chemistry for small-molecule drug discovery
AI HealthcareDrug Discovery
Genesis Molecular AI
Generative AI for small-molecule drug discovery
AI HealthcareDrug Discovery
Treeline Biosciences
Computational and experimental drug discovery for hard-to-drug cancer targets
AI MedicalDrug Discovery
Basecamp Research
Building a GPT for biology from the planet's largest proprietary genomic dataset
Drug Discovery
Nabla Bio
Generative AI for de novo antibody and protein design against tough drug targets
Drug Discovery
- What does Biomatter do?
- It uses generative AI and synthetic biology to design novel proteins and enzymes for industry, health, and the environment.
- What is Intelligent Architecture?
- Biomatter's generative platform for designing proteins and enzymes beyond natural evolution.
- Where is Biomatter based?
- Vilnius, Lithuania.
Discussion
Sign in to join the discussion.
Sign inExplore more around Biomatter
Contextual paths to related AI startups, deals and rankings.